Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.

23. maj 2013 opdateret af: Takeda

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes

The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

SYR-322 (alogliptin) is a selective, orally available inhibitor of dipeptidyl peptidase IV being developed as a treatment for type 2 diabetes mellitus. Dipeptidyl peptidase IV is the primary enzyme involved in the in vivo degradation of at least 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.

Pioglitazone HCl (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan). Pioglitazone HCl depends on the presence of insulin for its mechanism of action.

This study will assess the effects of alogliptin and alogliptin coadministered with pioglitazone HCl on postprandial lipid and lipoprotein metabolism in participants with type 2 diabetes. Individuals who participate in this study will be required to commit to a screening visit and up to 6 additional visits at the study center. Study participation is anticipated to be about 20 weeks (or approximately 5 months). Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations and electrocardiograms. At 3 of the visits a meal will be served that must be eaten within 10 minutes.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

71

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  • Diagnosis of type 2 diabetes
  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Either failed treatment with diet and exercise for 3 months prior to Screening or has been receiving a stable dose of metformin, sulfonylurea, nateglinide, or repaglinide for more than 3 months prior to Screening.
  • Inadequate glycemic control as defined by glycosylated hemoglobin concentration between 6.5 and 9.0%, inclusive.
  • Fasting plasma glucose less than 13.3 mmol per L.
  • Fasting serum triglyceride level of 1.7 to 5.0 mmol per L, inclusive.
  • Has not been receiving any lipid-lowering therapy within 3 months prior to Screening or on a stable statin and/or ezetimibe therapy (same drug and dose) for at least 3 months.
  • Body mass index greater than 23 kg/m2 and less than 45 kg/m2.
  • If has regular use of other, non-excluded medications, must be on a stable dose for at least 4 weeks prior to Screening. Use of as needed prescription medications and over-the-counter medications is allowed at the discretion of the investigator.
  • Is to be Apolipoprotein E 3/3 or Apolipoprotein E 3/4 phenotype positive prior to baseline.

Exclusion Criteria

  • History of type 1 diabetes.
  • History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.
  • Diastolic blood pressure greater than 100 mm Hg or a systolic blood pressure of greater than 160 mm Hg.
  • History of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study medication.
  • Hemoglobin less than 120 g per L for males and less than100 g per L for females.
  • Alanine transaminase level greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.
  • Serum creatinine level greater than 133 μmol per L.
  • Fasting total cholesterol greater than 6.5 mmol per L.
  • New York Heart Association heart failure of any Class (I-IV) regardless of therapy.
  • History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  • History of acute metabolic diabetic complications.
  • History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • History of infection with human immunodeficiency virus.
  • History of diabetic gastro paresis.
  • History of gastric bypass surgery.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo QD
Medicin: Placebo
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Andre navne:
  • Actos
  • SYR-322
  • AD-4833
Eksperimentel: Alogliptin 25 mg QD
Medicin: Alogliptin
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Andre navne:
  • SYR-322
  • SYR110322
Eksperimentel: Alogliptin 25 mg QD + Pioglitazone 30 mg QD
Medicin: Alogliptin and Pioglitazone
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
Andre navne:
  • Actos
  • SYR-322
  • SYR110322
  • AD-4833
  • alogliptin

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.
Tidsramme: Baseline and Week 16.
The change in postprandial (after eating a meal) incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC (0-8h)) postdose at week 16 relative to baseline.
Baseline and Week 16.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4.
Tidsramme: Baseline and Week 4.
The change in postprandial incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC(0-8h)) postdose at week 4 relative to baseline.
Baseline and Week 4.
Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters.
Tidsramme: Baseline, Week 4 and Week 16.
The change in postprandial incremental area under the plasma concentration-time curve for very-low-density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL2 cholesterol, VLDL2 triglycerides, chylomicron cholesterol, chylomicron triglycerides, intermediate-density lipoprotein (IDL) cholesterol, and IDL triglycerides from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters.
Tidsramme: Baseline, Week 4 and Week 16.
Postprandial incremental area under the curve changes for very-low-density lipoprotein (VLDL) Apo B-48, VLDL Apo B 100, VLDL2 Apo B-48, VLDL2 Apo B 100, chylomicron Apo B-48, chylomicron Apo B 100, and intermediate density lipoprotein (IDL) Apo B-48, IDL Apo B 100, and triglyceride-rich remnant (TRR) lipoproteins from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.
Baseline, Week 4 and Week 16.
Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1)
Tidsramme: Baseline, Week 4 and Week 16.
Postprandial changes over time at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Postprandial Changes Over Time From Baseline for Glucose
Tidsramme: Baseline, Week 4 and Week 16.
Postprandial changes over time at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Postprandial Changes Over Time From Baseline for Insulin
Tidsramme: Baseline, Week 4 and Week 16.
Postprandial changes over time at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Postprandial Changes Over Time From Baseline for Glucagon
Tidsramme: Baseline, Week 4 and Week 16.
Postprandial changes over time at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Glycosylated Hemoglobin
Tidsramme: Baseline, Week 8 and Week 16.
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.
Baseline, Week 8 and Week 16.
Change From Baseline in Fasting Plasma Glucose
Tidsramme: Baseline, Week 4, Week 8 and Week 16.
The change in fasting plasma glucose collected at each week indicated relative to baseline.
Baseline, Week 4, Week 8 and Week 16.
Change From Baseline in Postprandial C-Peptide
Tidsramme: Baseline, Week 4 and Week 16.
The change in postprandial C-peptide collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Postprandial Proinsulin
Tidsramme: Baseline, Week 4 and Week 16.
The change in postprandial proinsulin collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP)
Tidsramme: Baseline, Week 4 and Week 16.
The change in hs-CRP collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Adiponectin
Tidsramme: Baseline, Week 4 and Week 16.
The change in adiponectin collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM)
Tidsramme: Baseline, Week 4 and Week 16.
The change in VCAM collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM)
Tidsramme: Baseline, Week 4 and Week 16.
The change in ICAM collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in e-Selectin
Tidsramme: Baseline, Week 4 and Week 16.
The change in e-Selectin collected at each week indicated relative to baseline.
Baseline, Week 4 and Week 16.
Change From Baseline in Endothelial Function Through Pulse Wave Tonometry
Tidsramme: Baseline and Week 16.
Pulse wave tonometry performed before the meal and 2 hours postmeal using one recording consisting of 15 to 20 sequentially recorded radial artery waveforms collected at each assessment.
Baseline and Week 16.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Takeda

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juli 2007

Primær færdiggørelse (Faktiske)

1. december 2009

Studieafslutning (Faktiske)

1. december 2009

Datoer for studieregistrering

Først indsendt

4. april 2008

Først indsendt, der opfyldte QC-kriterier

9. april 2008

Først opslået (Skøn)

10. april 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

27. maj 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. maj 2013

Sidst verificeret

1. maj 2013

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • SYR-322_301
  • 2007-000486-38 (EudraCT nummer)
  • U1111-1113-2081 (Registry Identifier: WHO)
  • NL22649.029.08 (Registry Identifier: CCMO)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Diabetes mellitus

Kliniske forsøg med Placebo

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Guinea

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner